Key Points:
- Ad26.COV2.S vaccine has shown strong immune response
- The Johnson & Johnson vaccine is still in its early clinical trial stage.
- The vaccine is said to begin its Phase 3 by the end of 2020 or the early 2021.
Johnson & Johnson Company has come up with its vaccine to fight the Covid-19 virus. A Strong immune response against the novel Coronavirus was seen in a single dose of Johnson & Johnson’s experimental COVID-19 vaccine. As per results shown on Friday, the vaccine is being trialed before-hand when it is still in its early-to-mid clinical trial stage.
At the two different doses, the vaccine, called Ad26.COV2.S, was equally endured, the results showed. A single shot, versus a rival two-dose approach being tested by Moderna Inc and Pfizer Inc, could make simpler the giving out of the vaccine.
However, it is uncertain whether elderly people, one of the populations most at risk from the virus, will be protected to the same degree as younger people with the J&J vaccine.
Johnson & Johnson said it expected to know by December whether its vaccine was effective or not. That is roughly in line with the schedules announced by Modern and AstraZeneca as well. Pfizer, in contrast, has also said it hoped to get the efficacy information by the end of October itself.
– 99% of the participants age 18 to 55 in both dose groups had developed antibodies against the virus 29 days after getting vaccinated.
– Side effects, like fever, headache, fatigue, body aches and injection-site pain, were mild and resolved after a couple of days.
– Some of the participants will be receiving a second shot of the vaccine as part of the trial.
Johnson & Johnson says it plans to enroll 60,000 adult volunteers at more than 200 sites in the US and internationally.
JUST IN: #JNJ has announced the start of our Phase 3 clinical trial for our investigational #COVID19 vaccine candidate. We are fully focused on developing a safe, effective and urgently-needed preventive solution for people around the world. Read more: https://t.co/gi5PpMMcgu pic.twitter.com/vx0tpuH6Tc
— Johnson & Johnson (@JNJNews) September 23, 2020
The Johnson & Johnson vaccine is the fourth in the United States to enter the final phase of clinical trials.
